Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002349378 | SCV002619720 | likely pathogenic | Cardiovascular phenotype | 2016-04-12 | criteria provided, single submitter | clinical testing | The p.V338F variant (also known as c.1012G>T), located in coding exon 6 of the ACVRL1 gene, results from a G to T substitution at nucleotide position 1012. The valine at codon 338 is replaced by phenylalanine, an amino acid with highly similar properties. A novel missense alteration at the same codon (p.V338D) was reported in an individual with a clinical diagnosis of HHT. The alteration co-segregated with disease in this proband and two affected children (Tørring PM, et al. Clin. Genet. 2014 Aug; 86(2):123-33). The p.V338F variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on internal structural analysis, this variant is located in a catalytic loop of the C-terminal kinase domain next to an ATP binding crevice, and is likely to result in perturbation of function (Ricard N, et al. Blood. 2010 Sep; 116(9):1604-12; Kerr G, et al. Angiogenesis. 2015 Apr; 18(2):209-17). Based on the majority of available evidence to date, p.V338F is likely to be pathogenic. |